Quantification of trans -3,4,5,4′-tetramethoxystilbene in rat plasma by HPLC: Application to pharmacokinetic study

Journal of Agricultural and Food Chemistry

Volumn 59, Issue 4, 2011, Pages 1072-1077

  Lin, Hai Shu ^a   Zhang, Wei ^a   Go, Mei Lin ^a   Tringali, Corrado ^b   Spatafora, Carmela ^b   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

absolute oral bioavailability; HPLC; pharmacokinetics; trans 3,4,5,4 Tetramethoxystilbene

Indexed keywords

ABSOLUTE ORAL BIOAVAILABILITY; CHEMOTHERAPEUTIC AGENTS; CHROMATOGRAPHIC SEPARATIONS; COLORECTAL CANCER; HPLC; HPLC METHOD; INTRAVENOUS ADMINISTRATION; LIMIT OF QUANTIFICATIONS; PHARMACOKINETIC PROFILES; PHARMACOKINETIC STUDIES; RAT PLASMA; RELATIVE STANDARD DEVIATIONS; REVERSED PHASE HPLC;

ACETONITRILE; BIOCHEMISTRY; PHARMACOKINETICS; PLASMA (HUMAN);

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

3,4,5,4' TETRAMETHOXYSTILBENE; 3,4,5,4'-TETRAMETHOXYSTILBENE; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; RAT; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; STILBENES;

RATTUS;

EID: 79951754053     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf1043019     Document Type: Article

References (31)

1. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence Nat. Rev. Drug Discov. 2006, 5 (6) 493-506 (Pubitemid 44136961)
2. Gosslau, A.; Chen, M.; Ho, C. T.; Chen, K. Y. A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts Br. J. Cancer 2005, 92 (3) 513-521 (Pubitemid 40395532)
3. Sale, S.; Verschoyle, R. D.; Boocock, D.; Jones, D. J.; Wilsher, N.; Ruparelia, K. C.; Potter, G. A.; Farmer, P. B.; Steward, W. P.; Gescher, A. J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans -3,4,5,4′-tetramethoxystilbene Br. J. Cancer 2004, 90 (3) 736-744 (Pubitemid 38297218)
4. Pan, M. H.; Chang, Y. H.; Badmaev, V.; Nagabhushanam, K.; Ho, C. T. Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells J. Agric. Food Chem. 2007, 55 (19) 7777-7785 (Pubitemid 47522187)
5. Sale, S.; Tunstall, R. G.; Ruparelia, K. C.; Potter, G. A.; Steward, W. P.; Gescher, A. J. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans -3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells Int. J. Cancer 2005, 115 (2) 194-201 (Pubitemid 40586727)
6. Ahmad, F.; Bakar, S. A.; Ibrahim, A. Z.; Read, R. W. Constituents of the leaves of Piper caninum Planta Med. 1997, 63 (2) 193-194 (Pubitemid 27196099)
7. Li, H.; Wu, W. K.; Zheng, Z.; Che, C. T.; Yu, L.; Li, Z. J.; Wu, Y. C.; Cheng, K. W.; Yu, J.; Cho, C. H.; Wang, M. 2,3′,4,4′,5′- Pentamethoxy- trans -stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules Biochem. Pharmacol. 2009, 78 (9) 1224-1232
8. Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; Hamel, E. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization J. Med. Chem. 1991, 34 (8) 2579-2588
9. Pati, H.; Taherbhai, Z.; Forrest, L.; Wicks, M.; Bailey, S.; Staples, A.; Stewart, M.; Pennington, W.; Harris, J.; Lee, M. A stereospecific route for the preparation of trans -combretastatin analogs: synthesis and cytotoxicity Lett. Drug Des. Discov. 2004, 1 (3) 275-278
10. Gosslau, A.; Pabbaraja, S.; Knapp, S.; Chen, K. Y. trans-and cis -stilbene polyphenols induced rapid perinuclear mitochondrial clustering and p53-independent apoptosis in cancer cells but not normal cells Eur. J. Pharmacol. 2008, 587 (1-3) 25-34
11. Ma, Z.; Molavi, O.; Haddadi, A.; Lai, R.; Gossage, R. A.; Lavasanifar, A. Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol Cancer Chemother. Pharmacol. 2008, 63 (1) 27-35
12. Lu, J.; Ho, C. H.; Ghai, G.; Chen, K. Y. Resveratrol analog, 3,4,5,4′-tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts Carcinogenesis 2001, 22 (2) 321-328 (Pubitemid 32175522)
13. Heynekamp, J. J.; Weber, W. M.; Hunsaker, L. A.; Gonzales, A. M.; Orlando, R. A.; Deck, L. M.; Jagt, D. L. Substituted trans -stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor ?-induced activation of transcription factor nuclear factor ?B J. Med. Chem. 2006, 49 (24) 7182-7189 (Pubitemid 44886003)
14. Murias, M.; Handler, N.; Erker, T.; Pleban, K.; Ecker, G.; Saiko, P.; Szekeres, T.; Jäger, W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship Bioorg. Med. Chem. 2004, 12 (21) 5571-5578 (Pubitemid 39304056)
15. Lin, J. H.; Lu, A. Y. Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol. Rev. 1997, 49 (4) 403-449 (Pubitemid 28030947)
16. Zhang, W.; Go, M. L. Quinone reductase induction activity of methoxylated analogues of resveratrol Eur. J. Med. Chem. 2007, 42 (6) 841-850 (Pubitemid 46810071)
17. Lin, H. S.; Choo, Q. Y.; Ho, P. C. Quantification of oxyresveratrol analog trans -2,4,3′,5′-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study Biomed. Chromatogr. 2010, 24 (12) 1373-1378
18. Lin, H. S.; Tringali, C.; Spatafora, C.; Choo, Q. Y.; Ho, P. C. LC determination of trans -3,5,3′,4′,5′-pentamethoxystilbene in rat plasma Chromatographia 2010, 72, 827-832
19. National Advisory Committee for Laboratory Animal Research. Guidelines on the Care and Use of Animals for Scientific Purposes, Singapore 2004; http://www.ava.gov.sg/NR/rdonlyres/C64255C0-3933-4EBC-B869-84621A9BF682/13557/ Attach3-AnimalsforScientificPurposes.PDF.
20. Lin, H. S.; Ho, P. C. A rapid HPLC method for the quantification of 3,5,4′-trimethoxy- trans -stilbene (TMS) in rat plasma and its application in pharmacokinetic study J Pharm Biomed Anal 2009, 49 (2) 387-392
21. Lin, H. S.; Yue, B. D.; Ho, P. C. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study Biomed. Chromatogr. 2009, 23 (12) 1308-15
22. Lin, H. S.; Tringali, C.; Spatafora, C.; Wu, C.; Ho, P. C. A simple and sensitive HPLC-UV method for the quantification of piceatannol analog trans -3,5,3′,4′-tetramethoxystilbene in rat plasma and its application for a pre-clinical pharmacokinetic study J. Pharm. Biomed. Anal. 2010, 51 (3) 679-684
23. Lin, H. S.; Zhang, W.; Go, M. L.; Choo, Q. Y.; Ho, P. C. Determination of Z -3,5,4′-trimethoxystilbene in rat plasma by a simple HPLC method: application in a pre-clinical pharmacokinetic study J. Pharm. Biomed. Anal. 2010, 53 (3) 693-697
24. Hurst, S.; Loi, C. M.; Brodfuehrer, J.; El-Kattan, A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans Expert Opin. Drug Metab. Toxicol. 2007, 3 (4) 469-489 (Pubitemid 351324958)
25. Chan, O. H.; Stewart, B. H. Physicochemical and drug-delivery considerations for oral drug bioavailability Drug Discov. Today 1996, 1 (11) 461-473 (Pubitemid 126393548)
26. Das, S.; Lin, H. S.; Ho, P. C.; Ng, K. Y. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol Pharm. Res. 2008, 25 (11) 2593-2600
27. Subbaramaiah, K.; Dannenberg, A. J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment Trends Pharmacol. Sci. 2003, 24 (2) 96-102 (Pubitemid 36135884)
28. McErlane, V. M.; Ulhaq, S.; Hylands, F. M.; Honess, D. J.; Stratford, M. R.; Everett, S. A.; Wilsher, N.; Butler, P. J.; Potter, G. A. Pre-clinical development of DMU212, a cytochrome P450 CYP1A1 and CYP1B1-activated prodrug for targeted cancer therapy Proc. Amer. Assoc. Cancer Res 2005, 46, 3953
29. Gibson, P.; Gill, J. H.; Khan, P. A.; Seargent, J. M.; Martin, S. W.; Batman, P. A.; Griffith, J.; Bradley, C.; Double, J. A.; Bibby, M. C.; Loadman, P. M. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development Mol. Cancer Ther. 2003, 2 (6) 527-534
30. Murray, G. I.; Taylor, M. C.; McFadyen, M. C.; McKay, J. A.; Greenlee, W. F.; Burke, M. D.; Melvin, W. T. Tumor-specific expression of cytochrome P450 CYP1B1 Cancer Res. 1997, 57 (14) 3026-3031 (Pubitemid 27315056)
31. Chang, H.; Su, J. M.; Huang, C. C.; Liu, L. C.; Tsai, C. H.; Chou, M. C.; Lin, P. Using a combination of cytochrome P450 1B1 and beta-catenin for early diagnosis and prevention of colorectal cancer Cancer Detect. Prev. 2005, 29 (6) 562-569 (Pubitemid 41758496)